Shares of Mylan NV (NASDAQ:MYL) have earned a consensus rating of “Buy” from the twenty-three ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $33.06.
MYL has been the topic of a number of recent research reports. BidaskClub raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, June 20th. Royal Bank of Canada lowered Zayo Group from an “outperform” rating to a “sector perform” rating and upped their price objective for the stock from $33.00 to $35.00 in a research report on Wednesday, May 8th. Argus cut their price objective on Mylan to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 27th. Barclays reiterated a “hold” rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Finally, Morgan Stanley reiterated an “overweight” rating and set a GBX 2,280 ($29.79) target price on shares of Anglo American in a research note on Wednesday, May 8th.
Several hedge funds have recently modified their holdings of MYL. Pzena Investment Management LLC boosted its stake in Mylan by 0.3% in the first quarter. Pzena Investment Management LLC now owns 21,027,676 shares of the company’s stock valued at $595,924,000 after acquiring an additional 71,010 shares in the last quarter. Geode Capital Management LLC boosted its stake in Mylan by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock valued at $215,460,000 after acquiring an additional 1,026,731 shares in the last quarter. FIL Ltd boosted its stake in Mylan by 14.1% in the first quarter. FIL Ltd now owns 6,468,868 shares of the company’s stock valued at $183,327,000 after acquiring an additional 799,051 shares in the last quarter. Norges Bank acquired a new position in Mylan in the fourth quarter valued at $169,463,000. Finally, Dimensional Fund Advisors LP boosted its stake in Mylan by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,120,516 shares of the company’s stock valued at $167,704,000 after acquiring an additional 538,334 shares in the last quarter. Hedge funds and other institutional investors own 83.77% of the company’s stock.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.03. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The business had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same quarter in the prior year, the company earned $0.96 earnings per share. The company’s revenue was down 7.0% on a year-over-year basis. On average, equities research analysts expect that Mylan will post 4.28 EPS for the current year.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: What is a management fee?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.